aXichem carries out a directed share issue of approximately SEK 0.9 million to guarantors of TO1A

aXichem AB (publ) (”aXichem” or the “Company”) has today, in line with previously communicated information, resolved on a directed new share issue of 946,437 shares of class A to the investors who has provided a so-called “top-down guarantee” in connection with the exercise period of the warrants of series TO1A. The shares were issued at subscription price of SEK 0.95 per share, corresponding to the subscription price in the TO1A exercise. Through the directed share issue, the Company will receive approximately SEK 0.9 million before issue costs.

As previously communicated, the Company has in connection with the exercise of warrants of series TO1A received, free of charge, so-called top-down guarantees amounting to a total of SEK 2.0 million, corresponding to approximately 11 percent of the issue proceeds of TO1A. Since the subscription rate of TO1A amounted to approximately 95 percent, the board of directors has resolved to utilize the top-down guarantee for the issuance of 946,437 shares of class A, corresponding to approximately SEK 0.9 million and approximately 5 percent of the issued proceeds from TO1A. Accordingly, the board of directors of aXichem has today, based on the authorization from the annual general meeting on 19 June 2024, resolved on a directed new issue of 946,437 shares of class A in the Company.

The shares have been subscribed for by Per Vasilis (378,575 shares of class A), Filippa Vasilis (378,575 shares of class A) and Pronator Invest AB (189,287 shares of class A), in accordance with their respective guarantee commitments.

The subscription price in the directed share issue has been negotiated with the guarantors and amounted to SEK 0.95 per share, corresponding to the exercise price for warrants of series TO1A. The board of aXichem deems that the subscription price is in accordance with market terms.

The reasons for the deviation from the shareholders’ pre-emptive rights is to ensure that the Company receives proceeds corresponding to full exercise of the warrants of series TO1A. The board of directors deems that the now chosen course of action will give the Company access to the required capital in a cost-effective manner and without exposing the Company to market volatility and time-consumption that a right issue or other available alternatives would entail. Against this background, the board of directors has assessed that the directed share issue is in the best interest of both the Company and its shareholders.

Registration of the directed share issue with the Swedish Companies Registration Office is expected to occur during the beginning of November 2024 at the latest. Through the directed share issue, the number of shares of class A will increase by 946,437, from 58,168,468 to 59,114,905 shares, and the share capital will increase by SEK 189,287.40, from SEK 11,633,693.60 to SEK 11,822,981, corresponding to a dilution of approximately 1.6 percent. The stated figures include changes due to the exercise of warrants series TO1A.

For more information:

Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355, Email: [email protected]

Certified adviser for aXichem is Västra Hamnen Corporate Finance AB.

The information was submitted, through the agency of the above contact person, for publication on October 24, 2024, at 15:00 CEST.

About aXichem

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey, as an ingredient in food supplements for gut health, weight control and sports and exercise, and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. More information is available at www.axichem.com.